Montreal, Quebec (PRWEB) September 20, 2012
According to Montreal plastic surgeon Bill Papanastasiou, more than 70% of women who have undergone breast augmentation surgery claim to have chosen implants that were too small. “This is because current methods used to simulate the surgery’s outcome are fairly archaic and clearly inadequate in guiding patients with their choices prior to surgery. Canfield’s VECTRA 3D® imaging technology will finally allow Montreal women to choose the size of implant that suits them and increase their satisfaction level following breast augmentation.”
Offered exclusively at Dr. Papanastasiou’s clinic, VECTRA 3D® imaging technology revolutionizes plastic surgery by taking photographs of the patient and creating a realistic, three-dimensional image that can be viewed from any angle. This personalized image can be adjusted according to the different sizes of implant the patient is considering. “This feature is extremely important because it allows a woman to make an informed choice and clearly see the implant’s effect on her body image. I also see that the technology often generates a much more open dialogue between surgeon and patient, leading to results that meet the patient’s expectations,” added Dr. Papanastasiou.
Dr. Papanastasiou also believes that this technology will maximize women’s satisfaction level with respect to their surgery. It will reduce women’s insecurity about surgical outcomes and significantly enhance the decision-making process since only 5% of women interested in this procedure currently go through with it. Research shows that women considering breast augmentation wait an average of two years before going ahead with the surgery.
With more than 25 years of experience as a plastic surgeon, Dr. Bill Papanastasiou is recognized as a North American leader in breast augmentation surgery. He obtained his degree from McGill University in 1986 and is a member of and lecturer for various plastic surgery associations. He has held teaching positions at McGill University and the Université de Montréal, and is currently associated with St. Mary’s Hospital Center.
VECTRA 3D® technology was developed by Canfield Scientific Inc., a New Jersey-based company, and is distributed in Canada by Allergan.